ClinicalTrials.gg
RecruitingNCT06345781Updated Mar 31, 2026

Abdominal Functional Electrical Stimulation to Improve Bowel Function in Spinal Cord Injury

An interventional study of Abdominal Functional Electrical Stimulation in Spinal Cord Injuries and Neurogenic Bowel, sponsored by Craig Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Craig Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Spinal Cord Injuries by Craig Hospital — 6 open to participants now, 7 under way, none of them phase 3. Spinal Cord Injuries · Craig Hospital.

Planned enrollment
15th of 17
15 · median 37
Started
2025
with 3 others
No phase
14 of 21
3 open now
Registered
17th of 21
by date

Among the 21 studies in Spinal Cord Injuries by Craig Hospital, this one is the 15th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 with no phase, and was the 17th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

6 of the 21 studies in Spinal Cord Injuries by Craig Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Spinal Cord Injuries by Craig Hospital, or all of them as a file.
02

Study summary

The primary objective of this study is to gather information about the effectiveness of abdominal FES to improve bowel management time (BMT) for people with chronic SCI. This study will also evaluate whether abdominal FES can improve: 1) bowel-related quality of life, 2) participant-reported bowel function, 3) bowel management strategy, 4) bladder symptoms, and 5) unplanned hospital admissions. In addition, we will also explore participant perspectives and experiences about the stimulation sessions and use of the device.

03

Conditions studied

  • Spinal Cord Injuries
  • Neurogenic Bowel

Keywords

  • Spinal Cord Injury
  • Functional Electrical Stimulation (FES)
  • Neurogenic Bowel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chronic SCI (> 12 months since injury) above the level of T11
  2. > 18 years of age
  3. a measurable and consistent start and end event is determinable for the bowel routine

    • Start events include: 1) enema insertion, 2) digital stimulation, 3) hot drink or initiation of the gastrocolic reflex, 3) abdominal massage, or 4) other, as determined by the participant and research team.
    • Ending events include: 1) final digital stimulation, 2) when evacuation has ceased, or 3) other, as determined by the participant and research team.
  4. Portable smart device with video capabilities and internet access
  5. Willingness to access and/or download Zoom (videoconferencing software)

Exclusion criteria

Exclusion Criteria:

  1. American Spinal Injuries Association (ASIA) Impairment Scale (AIS) E
  2. Self-reported bowel management time (BMT) of \<30 minutes
  3. Current bowel conditions such as gastro-esophageal reflux, bowel obstruction, Crohn's disease, or diverticulitis
  4. Physical obstacles that prevent AFES (e.g., pregnancy, abdominal trauma, cardiac pacemaker, or other implanted electromedical devices)
  5. Stoma or colostomy
  6. No response to AFES (e.g., lower motor neuron impairment)
  7. History of gastrointestinal surgery within the past 3 months
  8. Severely obese participants (>40 )
  9. Primary language other than English
  10. Previous history of uncontrolled, recurrent episodes of AD
  11. Resting systolic blood pressure (BP) reported as >140 mmHg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Abdominal Functional Electrical Stimulation

    All participants enrolled will receive the intervention.

    Behavioral: Abdominal Functional Electrical Stimulation

Interventions

  • BehavioralAbdominal Functional Electrical Stimulation

    Functional electrical stimulation electrodes will be applied to the abdomen during a bowel program to assess effects of stimulation on bowel management time.

06

What researchers measure

Primary outcomes

  1. Bowel Management Time (BMT)

    This is measured by recording start and end time of bowel management session in study diary.

    Time frame: Daily (Weeks 1-10)

Secondary outcomes

  1. Bowel Management Strategy

    This will be measured via analysis of daily diary entries regarding bowel movements (time taken and frequency), dietary changes or inconsistencies, and use of laxatives and manual procedures. The bowel diary will be completed daily throughout the study by participants and/or their caregivers.

    Time frame: Daily (Weeks 1-10)

  2. Stimulation Dose

    This will be recorded by the participant. Participants will be asked to record the total time of active stimulation as displayed by the stimulation counter/timer and the intensity of the stimulation (milliamps) for each BM session in their bowel diary. The stimulation device will also record number of times the device button is depressed and duration in seconds, which can be downloaded at a later date by the research team providing further detail on stimulation dose.

    Time frame: During active stimulation period (Weeks 3-7)

  3. EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Questionnaire

    Quality of Life measure

    Time frame: Week 1, Week 3, Week 7, Week 10

  4. International Spinal Cord Society's (ISCoS) International SCI Bowel Function Basic Data Set Questionnaire

    This instrument measures participant-reported bowel function bowel function.

    Time frame: Week 1, Week 3, Week 7, Week 10

  5. Visual Analog Scale (VAS)

    This instrument measures participant perceptions of bowel function satisfaction on a rating scale from 0-100.

    Time frame: Week 1, Week 3, Week 7, Week 10

  6. Neurogenic Bladder Symptom Score (NBSS)

    This instrument measures neurogenic bladder symptoms

    Time frame: Week 1, Week 3, Week 7, Week 10

  7. Intervention Acceptability

    Qualitative and quantitative analysis of abdominal functional stimulation (AFES) use will be measured at the end of the active trial period, using both open-ended and 10-scored theoretical framework of acceptability questions to gain the perspective of people with lived experience of SCI on the use of AFES during a bowel routine

    Time frame: Week 7

  8. Intervention Safety

    This will be determined by the reporting and summarization of any adverse events associated with the interventions. Participants will be instructed to record any adverse events in their bowel diaries and to call study staff immediately to review. Unplanned hospital visits will also be recorded in the study diary.

    Time frame: Daily (Weeks 0-10)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2026, 13 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 13 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 3, 2024
StartActual
Apr 30, 2025
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06345781
Lead sponsor
Craig Hospital
Collaborators
Neuroscience Research Australia
Responsible party
Candace Tefertiller (Executive Director of Research and Evaluation, Craig Hospital) — Principal investigator
First posted
Apr 3, 2024
Start date
Apr 30, 2025
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Mar 31, 2026

Study contacts

Candy Tefertiller
Contact
ctefertiller@craighospital.org
303-789-8000
Bria Mellick
Contact
bmellick@craighospital.org
303-789-8757

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion